BD Gains Access to University College London Patient Samples for Assay Development | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Becton Dickinson and UCL Business, a subsidiary of University College London, announced this week an agreement that could lead to biomarker assays for ovarian and breast cancers.

The deal gives BD access to UCL's biobanks containing more than 200,000 human patient samples collected in prospective screening clinical trials for the detection and management of epithelial ovarian cancer. BD will use the samples to develop and validate biomarker assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."